Lineage Cell Therapeutics, Inc. (LCTX) Shows Vision Gains in Phase 1/2a OpRegen Trial [Yahoo! Finance]
Lineage Cell Therapeutics, Inc. (LCTX)
Company Research
Source: Yahoo! Finance
Lineage Cell Therapeutics, Inc. (NYSE:LCTX) is a clinical-stage biotech company developing allogeneic “off-the-shelf” cell therapies for neurological and ophthalmic disorders. Its proprietary platform engineers human cells to replace or support dysfunctional cells caused by degenerative diseases, injuries, or aging. In August 2025, the business reported positive 36-month Phase 1/2a results for RG6501 (OpRegen), a retinal pigment epithelial therapy for geographic atrophy, a form of age-related macular degeneration. Patients showed sustained vision improvements of +6.2 ETDRS letters, suggesting potential disease stabilization from a single administration. The data, presented at Clinical Trials at the Summit 2025, reinforces OpRegen's promise as a therapy licensed to Genentech and Roche for further development, positioning Lineage among the best penny stocks in the biotech space. Lineage Cell Therapeutics, Inc. (NYSE:LCTX) also treated its first chronic spinal cord injury patient in
Show less
Read more
Impact Snapshot
Event Time:
LCTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LCTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LCTX alerts
High impacting Lineage Cell Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LCTX
News
- Lineage Cell Therapeutics: OpRegen Makes It A Viable Speculative Buy [Seeking Alpha]Seeking Alpha
- Dimension Bio Announces Inaugural Clinical and Scientific Advisory BoardsPR Web
- Lineage Cell Therapeutics Inc (LCTX) Q3 2025 Earnings Call Highlights: Strategic Partnerships ... [Yahoo! Finance]Yahoo! Finance
- Lineage Cell Therapeutics GAAP EPS of -$0.13 misses by $0.10, revenue of $3.68M beats by $1.38M [Seeking Alpha]Seeking Alpha
- Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business UpdateBusiness Wire